Arrowhead Pharmaceuticals, Inc. (ARWR)

NASDAQ: ARWR · IEX Real-Time Price · USD
28.70
+0.86 (3.09%)
At close: Mar 27, 2024, 4:00 PM
28.20
-0.50 (-1.74%)
After-hours: Mar 27, 2024, 5:08 PM EDT
3.09%
Market Cap 3.56B
Revenue (ttm) 181.74M
Net Income (ttm) -296.81M
Shares Out 123.90M
EPS (ttm) -2.77
PE Ratio n/a
Forward PE 111.11
Dividend n/a
Ex-Dividend Date n/a
Volume 510,513
Open 28.21
Previous Close 27.84
Day's Range 27.85 - 28.87
52-Week Range 20.67 - 42.48
Beta 0.72
Analysts Buy
Price Target 55.08 (+91.92%)
Earnings Date Apr 30, 2024

About ARWR

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 16, 1993
Employees 525
Stock Exchange NASDAQ
Ticker Symbol ARWR
Full Company Profile

Financial Performance

In 2023, ARWR's revenue was $240.74 million, a decrease of -1.03% compared to the previous year's $243.23 million. Losses were -$205.28 million, 16.6% more than in 2022.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for ARWR stock is "Buy." The 12-month stock price forecast is $55.08, which is an increase of 91.92% from the latest price.

Price Target
$55.08
(91.92% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has initiated an Expanded Access Program (EAP) to make investigational plozasiran av...

2 days ago - Business Wire

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a double-blinded, placebo-controlled, dos...

19 days ago - Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TD Cowen's 44th Annual...

23 days ago - Business Wire

Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 first quarter ended December 31, 2023. The Company is ...

7 weeks ago - Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2024, at 4:30 p.m. ET to discu...

2 months ago - Business Wire

Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that on January 5, 2024, it closed the previously announced underwritten registered offering...

2 months ago - Business Wire

Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of an underwritten registered offering of 15,790,000 shares of its common stock,...

3 months ago - Business Wire

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 28, 2023, th...

3 months ago - Business Wire

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO...

3 months ago - Business Wire

Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the upcoming 42nd Annual J.P. Morgan Healthcare Conferenc...

3 months ago - Business Wire

Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2023. The company is hosting a con...

4 months ago - Business Wire

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO...

4 months ago - Business Wire

Arrowhead Pharmaceuticals to Participate in Piper Sandler 35th Annual Healthcare Conference

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in a fireside chat at the upcoming Piper Sandler 35th An...

4 months ago - Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Year End Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 29, 2023, at 4:30 p.m. ET to disc...

4 months ago - Business Wire

Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented new Phase 2 clinical data from the ongoing SHASTA-2 and MUIR studies of plozasiran (ARO-APOC3...

4 months ago - Business Wire

Arrowhead Pharmaceuticals to Participate in Jefferies London Healthcare Conference

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in a fireside chat at the upcoming Jefferies London Heal...

5 months ago - Business Wire

Arrowhead Pharmaceuticals to Present New Phase 2 Clinical Data on Cardiometabolic Pipeline at AHA 2023

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present new Phase 2 clinical data from the ongoing SHASTA-2 and MUIR studies of ...

5 months ago - Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming October 2023 Conferences

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2023 Annual Northeast ...

6 months ago - Business Wire

Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced data on its pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates, in...

7 months ago - Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming September 2023 Conferences

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Citi's 18th Annual Bio...

7 months ago - Business Wire

Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2023. The company is hosting a...

8 months ago - Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Third Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 7, 2023, at 4:30 p.m. ET to discuss...

8 months ago - Business Wire

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2 clinical trial of ARO...

9 months ago - Business Wire

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed an application for approval to initiate a Phase 1 clinical trial of ARO-SO...

9 months ago - Business Wire

Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented updated results from the Phase 2 SEQUOIA clinical study of investigational fazirsiran (TAK-99...

9 months ago - Business Wire